Results 111 to 120 of about 139,370 (300)

Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation [PDF]

open access: yes, 2010
<p><b>Background and Purpose:</b> Mechanisms of early neurologic deterioration after treatment with intravenous, recombinant, tissue-type plasminogen activator (IV rt-PA) include symptomatic intracerebral hemorrhage (SICH) and early ...
Awadh, M.   +5 more
core   +1 more source

Electrochemical Three‐Component Synthesis of Vinyl Sulfonamides via Decarboxylative Sulfonylation of Cinnamic Acids

open access: yesChemSusChem, EarlyView.
An efficient, metal‐free electrochemical three‐component reaction of cinnamic acids, SO2, and amines to access (E)‐β‐styryl sulfonamides is reported. Utilizing graphite electrodes and SO2 stock solutions, this decarboxylative protocol proceeds under mild conditions with high regio‐ and stereoselectivity.
Po‐Chung Chien   +2 more
wiley   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro   +15 more
wiley   +1 more source

Antiplatelet Therapy [PDF]

open access: yesCirculation, 2003
Ian Conde-Pozzi, Neal S. Kleiman
  +5 more sources

Real-world Data of Antithrombotic Therapy in Neuroendovascular Therapy: Analysis of JR-NET 4

open access: yesNeurologia Medico-Chirurgica
As the number of neuroendovascular therapies in Japan increases, the current trends in periprocedural antithrombotic therapy must be understood. We retrospectively analyzed data on periprocedural antithrombotic therapy in the Japanese Registry of ...
Nozomi SASAKI   +10 more
doaj   +1 more source

Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy: A Systematic Review and Meta‐analysis of 19 Studies

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundThe safety and long‐term outcome of systemic thrombolysis in patients receiving antiplatelet medications remain subjects of great clinical significance.
Shengyuan Luo   +3 more
doaj   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia   +2 more
wiley   +1 more source

Dynamics of hemostasis system parameters in assessing the risk of complications in the patients with acute myocardial infarction receiving antiplatelet therapy

open access: yesТрансплантология (Москва)
Background. Current treatment of patients with myocardial infarction is based on the strategy of early invasive coronary intervention in combination with dual antiplatelet therapy - with acetylsalicylic acid and a P2Y12 blocker of platelet adenosine ...
T. R. Gvindzhiliya   +6 more
doaj   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo   +7 more
wiley   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy